
    
      Patients are divided into 2 treatment groups; the groups are balanced with respect to viral
      load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2
      times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell
      count.
    
  